Drug Safety Update: March 2023

MHRA Drug Safety Update

March 2023

Terlipressin in patients with type 1 hepatorenal syndrome: new recommendations to reduce risks of respiratory failure and septic shock

New recommendations following a recent clinical trial which found that in patients with type 1 hepatorenal syndrome, terlipressin may cause serious or fatal respiratory failure at a frequency higher than previously known, and that terlipressin increases the risk of sepsis and septic shock. This advice is not relevant to use of terlipressin for bleeding oesophageal varices.

COVID-19 vaccines and medicines: updates for March 2023

Recent information relating to COVID-19 vaccines and medicines that has been published since the February 2023 issue of Drug Safety Update, up to 21 March 2023.

Letters and medicine recalls sent to healthcare professionals in February 2023

A summary of recent letters and notifications sent to healthcare professionals about medicines.

It's easy to report

Report a suspected adverse drug reaction online
or download the Yellow Card app

REPORT ONLINE

Drug Safety Update is a monthly newsletter from the Medicines and Healthcare products Regulatory Agency (MHRA) and its independent advisor the Commission on Human Medicines.

If you would like to share this with a friend or colleague, hit the Forward button or send them this link to view the email in a browser.

Unsubscribe or change your email address at any time on your subscriber preferences page.

If you have questions or problems with the subscription service, please visit subscriberhelp.govdelivery.com.

All other enquiries can be directed to email.support@mhra.gov.uk.

This is an automatically generated email. Please do not reply directly to this notification.
This service is provided to you at no charge by the Medicines and Healthcare products Regulatory Agency.